Zimmer Biomet Q2 sales rise 7.0% to $2.077 billion; raises 2025 adjusted EPS outlook
Zimmer Biomet reported second-quarter 2025 net sales of $2.077 billion, up 7.0% from a year earlier, and adjusted diluted EPS of $2.07, up 3.0%. GAAP diluted EPS fell to $0.77 from $1.18 as net earnings dropped to $152.8 million from $242.8 million, and the company cited higher acquisition-related and other costs. The company raised its full-year 2025 adjusted EPS guidance to $8.10-$8.30 from $7.90-$8.10 and tightened its reported revenue growth guidance to 6.7%-7.7%.
Key points
- Q2 2025 net sales were $2.077 billion, up 7.0% on a reported basis and 2.8% on an organic constant currency basis.
- GAAP diluted EPS was $0.77 versus $1.18 a year earlier; acquisition, integration and related charges were $78.9 million in the quarter.
- Full-year 2025 adjusted diluted EPS guidance rose to $8.10-$8.30 from $7.90-$8.10.
- Full-year 2025 reported revenue growth guidance was tightened to 6.7%-7.7% from 5.7%-8.2%.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.